Brought to you by:
Digging deep into DOACs for PAD post-revascularization in fight to stave off amputation
This advertorial is sponsored by ACHL. “It’s really sad—but it’s true: In the PAD [peripheral arterial disease] space, we’re really behind. We’re behind in our understanding of the physiology, the anatomy to some extent, the way the disease permeates through the…
FDA approves expanded PAD indication for rivaroxaban plus aspirin
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Food and Drug Administration (FDA) has approved an expanded peripheral arterial disease (PAD) indication for the Xarelto (rivaroxaban) vascular dose (2.5mg twice daily plus aspirin 100mg once daily) to…
VOYAGER PAD: Rivaroxaban plus aspirin should be considered after lower-extremity bypass regardless of conduit type
“A strategy of adding rivaroxaban 2.5mg twice daily to aspirin should be considered after lower extremity bypass regardless of conduit type,” concluded Nicholas Govsyeyev, MD, during the William J. von Liebig Forum at the Vascular Annual Meeting (VAM) in San…
The top 10 most popular Vascular Specialist stories in May
A pointed letter aimed at electronic health record (EHR) behemoth Epic, an argument in favor of endovascular treatment of ruptured abdominal aortic aneurysms (rAAAs) and the first-ever Corner Stitch column were among the best-read stories here on the Vascular Specialist…
ACC.21: VOYAGER PAD shows rivaroxaban ‘significantly’ reduced total ischemic events in PAD patients
Rivaroxaban combined with low-dose aspirin led to a significant reduction in the occurrence of total ischemic events in patients with symptomatic peripheral arterial disease (PAD) who underwent lower-extremity revascularization, according to researchers conducting the VOYAGER PAD trial. The findings were…
VOYAGER PAD: Rivaroxaban plus aspirin versus aspirin alone among CLTI patients undergoing revascularization reduced risk of adverse outcomes at three years
In one of the latest sub-analyses from the VOYAGER PAD trial, investigators found that rivaroxaban plus aspirin versus aspirin alone in the high-risk population of patients with critical limb-threatening ischemia (CLTI) undergoing lower-extremity revascularization reduced the risk of a first…
Latest VOYAGER PAD analysis finds no mortality and improved limb outcomes in drug-coated device cohort
Given the absence of a safety signal in data from the VOYAGER PAD trial, a new analysis examined the potential benefit of drug-coated device versus non-drug-coated device treatment for reducing limb outcomes. Connie Hess, MD, an associate professor of cardiology…
Janssen applies to FDA for new indication to expand use of rivaroxaban in PAD patients
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a new indication to expand the use of Xarelto (rivaroxaban) in patients with…
TCT 2020 late-breaking trials session features new data on drug-coated devices
Findings from a series of late-breaking trials in the endovascular field were delivered recently at TCT Connect (Oct. 14–18), the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF), held virtually, with the first from Connie N. Hess, MD,…
Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or avoided’ in PAD revascularization
“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence of clear benefit, clopidogrel exposure along with aspirin and rivaroxaban should be minimized or avoided to…